Compare BRID & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | ENTX |
|---|---|---|
| Founded | 1932 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 62.6M |
| IPO Year | 1995 | 2015 |
| Metric | BRID | ENTX |
|---|---|---|
| Price | $7.90 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 1.7K | ★ 100.4K |
| Earning Date | 06-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $174,257,000.00 | $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.86 |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $7.00 | $0.91 |
| 52 Week High | $8.73 | $3.22 |
| Indicator | BRID | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 49.67 |
| Support Level | $7.31 | $1.17 |
| Resistance Level | $8.07 | $1.37 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 64.74 | 48.21 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.